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We have determined the mechanism of neutralization of influenza virus infectivity by three antihemagglutinin monoclonal
antibodies, the structures of which we have analyzed before as complexes with hemagglutinin. The antibodies differ in their
sites of interaction with hemagglutinin and in their abilities to interfere in vitro with its two functions of receptor binding and
membrane fusion. We demonstrate that despite these differences all three antibodies neutralize infectivity by preventing
virus from binding to cells. Neutralization occurs at an average of one antibody bound per four hemagglutinins, a ratio
sufficient to prevent the simultaneous receptor binding of hemagglutinins that is necessary to attach virus to cells. © 2002cture; aINTRODUCTION
Protection against influenza is mediated by antihem-
agglutinin (HA) antibodies which also display virus infec-
tivity neutralization in vitro. Two lines of evidence sug-
gest that antibodies that participate in neutralization are
an important component of those that lead to protection
from infection: F(ab)2 preparations, devoid of the Fc-
dependent functions of the IgGs, were found to cure
infections in SCID mice (Palladino et al., 1995) and anti-
bodies that do not neutralize have generally been found
to be incapable of curing infections in these animals
(Gerhard et al., 1997). There are, however, uncertainties
about the mechanism of neutralization of influenza virus
infectivity (for reviews, see Dimmock, 1995; Klasse and
Sattentau, 2001; Parren and Burton, 2001). We have
therefore determined the structures of complexes of HA
with three antibodies that bind to three distinct epitopes
on HA (Barbey-Martin et al., 2002; Bizebard et al., 1995;
Daniels et al., 1983, 1987; Fleury et al., 1999; Skehel et al.,
1984) (Fig. 1) and studied the mechanism by which they
neutralize infectivity.
HA is involved in two steps of the process of influenza
virus infection. It binds the virus to its cellular receptors,
sialic acid residues of glycolipids, or glycolipids, and,
following endocytosis, it mediates the fusion of viral and
cellular membranes to permit entry of the genome–tran-
scriptase complex into the cell. HA is a trimer of identical
subunits. Structurally, each subunit consists of a mem-
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294brane-proximal helix-rich stem structure and a mem-
brane-distal receptor-binding globular domain (Wiley
and Skehel, 1987). The epitopes recognized by the three
antibodies we have studied are located on the receptor-
binding domain (Fig. 1). Two of them overlap with the
receptor-binding site and block access to it (Barbey-
Martin et al., 2002; Bizebard et al., 1995), while the third
is distant from the site (Fleury et al., 1999). The three
antibodies also differ in their abilities to prevent the
structural transition of HA that is required for fusion of
virus and cellular membranes: one of them blocks this
transition, the other two do not (Barbey-Martin et al.,
2002).
These three antibodies, therefore, are representative
of the range of neutralizing antibodies that react with
hemagglutinin and have provided the opportunity for us
to study the relationship of neutralization to the inhibition
of two successive steps in viral entry into the cell, in a
structurally defined context. We show that there is a
direct correlation between neutralization of virus infec-
tivity and inhibition of virus binding to cells and deter-
mine for each of the antibodies the number of molecules
that is required to achieve neutralization.
RESULTS AND DISCUSSION
The number of antibodies bound to virus in
neutralization
The number of antibody molecules bound to virus was
measured by incubating 125I-labeled antibody with virus
and separating bound from unbound antibody by centrif-
ugation. The antibody concentrations chosen coveredElsevier Science (USA)
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the range of concentrations in which neutralization of
infectivity varies between 0 and 100% and the concen-
tration required for each antibody to saturate the virus.
The data in Fig. 2 indicate that iodination of the antibod-
ies does not significantly affect virus–antibody interac-
tions (compare Fig. 3). We also checked that antibody
does not significantly detach from virus during separa-
tion of the complex by comparing our results to those
obtained by centrifugation through a sucrose solution in
which 125I-labeled antibody was present at the same
concentration as that incubated with virus.
Two of the antibodies, HC19(157) and HC45(63), neu-
tralize viral infectivity at a concentration at which they
saturate the virus (5  1010 M and 108 M, respectively),
whereas the third antibody, HC63(226), neutralizes at an
antibody concentration of 4  1010 M, lower than the
concentration required for saturation (2 108 M). These
results are consistent with observations made on the
basis of the structures, that whereas bound HC63(226)
Fabs extend from the hemagglutinin within the space
projected radially from a trimer, HC19(157) and HC45(63)
both bind on the sides of the trimer so that their com-
plexes occupy more space on the virus surface than the
trimer (Fig. 1). As a consequence of the limited space
available on the virus surface, saturation occurs at an
antibody:HA ratio that depends on the geometry of the
specific HA–antibody complex. Obviously, saturation of
virus by all antibodies with the ability to neutralize infec-
tivity occurs at a concentration higher than or equal to
that required for neutralization, which is what we find.
The antibody:HA spike ratio at which complete neu-
tralization by HC45(63) is achieved is ca. 1:3  1. For
HC19(157) and HC63(226), this ratio is ca. 1:5  1.5.
Neutralization by HC45(63) is therefore less efficient than
by HC19(157) or HC63(226) for two reasons: HC45(63)
has a lower avidity for hemagglutinin on the virus surface
FIG. 1. The Fab–HA complexes in this study. Ribbon diagrams of the
complexes showing one X31 HA monomer (each monomer contains
two polypeptide chains; one in blue forming the receptor-binding do-
main and the other in red forming the stem domain) and, from left to
right, the HC63(226), HC19(157), and HC45(63) Fabs (in green). Amino
acids in the receptor-binding site are shown as yellow space-filling
models. Each antibody is designated by a number as in previous work
together with (in parentheses) the residue in the sequence in which a
mutation has been identified that allows a variant virus to escape from
neutralization of infectivity by the antibody. These residues are colored
in red in the complexes.
FIG. 2. The relation between the number of antibody molecules
bound to a virus particle and neutralization. The ratios of the number of
virus plaques to the number of plaques formed without antibody (plain
lines, filled symbols) and the number of antibody molecules bound to 10
HAU of X31 virus (dashed lines, open symbols) are plotted on a
semilogarithmic scale as a function of antibody concentration
(HC19(157): E; HC63(226): ‚; HC45(63): ƒ). Each point of the latter
curves is the average of three independent experiments; plaque num-
ber ratios are the average of two experiments.
FIG. 3. The relation between inhibition of virus binding to cells by
antibodies and neutralization. The ratios of the number of virus plaques
to the number of plaques without antibody (plain lines, filled symbols)
and the ratio of cell-bound virus to cell-bound virus without antibody
(dashed lines, open symbols) are plotted on a semilogarithmic scale as
a function of antibody concentration (HC19(157): E; HC63(226): ‚;
HC45(63): ƒ). Each point is the average of three independent experi-
ments.
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(Fleury et al., 1999), and more HC45(63) antibody mole-
cules than HC19(157) or HC63(226) antibodies are re-
quired to bind to a virus to neutralize its infectivity.
Antibodies block virus attachment to cells
Viral attachment to cells is the first step in the infec-
tious cycle and its inhibition would appear to be an
effective way of preventing infection. Despite this, inhi-
bition of virus attachment to cells by antibodies has been
reported only rarely as the major contributor to infectivity
neutralization (see Ugolini et al., 1997 for an example and
Dimmock, 1995 for a review). There are, however, several
examples of inhibition of virus attachment by neutralizing
antibodies (Colonno et al., 1989; Flamand et al., 1993; He
et al., 1995; Smith et al., 1993). Using mixtures of anti-
bodies and labeled virus, we determined the amount of
radioactive virus that bound to cells as a function of
antibody concentration. In parallel we determined the
reduction in the number of infectious particles caused by
mixing a constant amount of virus with antibodies at
different concentrations. The data presented in Fig. 3
demonstrate a direct correlation between inhibition of
virus binding to cells and neutralization of infectivity.
From our structural analyses two of the antibodies,
HC19(157) and HC63(226), bind to the receptor-binding
site. Since their affinities for hemagglutinin (KD of Fabs
5  1010 M (Fleury et al., 1999) and 1.7  1010 M,
respectively) are much stronger than the affinities of the
receptor-binding site for sialyllactose receptor ana-
logues (KD 2  10
3 M) (Sauter et al., 1989), these anti-
bodies effectively block receptor binding. The third anti-
body HC45(63) also has a strong affinity for HA (KD of
Fab: 109 M) (Fleury et al., 1999) but binds to HA at a
distance from the receptor-binding site; the distance of
the nearest Fab atom to the receptor-binding site is 17 Å
(Fleury et al., 1999). Nevertheless, its inhibition of virus
binding at different concentrations correlates with its
neutralization of infectivity. Because of the low affinity of
the HA receptor-binding site for the virus receptor, sev-
eral HAs bind to a receptor upon attachment of a virus
particle to a cell. Presumably in the case of HC45(63), the
bound immunoglobulin, because of its large size, pre-
vents this simultaneous binding. Since HC45(63) binds
outside the receptor-binding site and closer to the virus
membrane than antibodies HC19(157) and HC63(226),
one would predict that it inhibits simultaneous binding of
several HAs to a viral receptor less efficiently than these
antibodies. Indeed, less HC19(157) or HC63(226) anti-
bodies than HC45(63) antibodies are required to bind to
a virus particle to neutralize its infectivity (see above).
One of the three antibodies we studied, HC63(226),
cross-links in vitromonomers in the hemagglutinin trimer
(Barbey-Martin et al., 2002) and prevents the low pH-
activated structural transition required for membrane fu-
sion (Skehel and Wiley, 2000). The epitopes of this anti-
body and of HC19(157) overlap with the receptor-binding
site and both antibodies have similar affinities for HA but,
as opposed to HC63(226), HC19(157) does not interfere
with the low pH-activated structural change. Since fusion
in endosomes follows receptor-binding and endocytosis,
in order for fusion inhibition to contribute to neutraliza-
tion, it would have to occur at an antibody concentration
at which virus still binds to cells. In the case of antibody
HC63(226) this would be at a very low antibody concen-
tration since complete neutralization by HC63(226) and
inhibition of virus binding to cells is achieved at an
antibody concentration of 5  1010 M. At this concen-
tration the ratio of the number of antibodies bound to
virus to the number of hemagglutinin spikes per virus is
close to 1:5 (see above and Fig. 2). In these conditions
the maximum proportion of hemagglutinin trimers that
are internally cross-linked is also 1:5, so that about 80%
of the hemagglutinins could still undergo the low pH
structural change. It is nevertheless possible that if the
HAs in virus particles are fixed in the plane of the mem-
brane and if the mechanism of membrane fusion re-
quires the cooperation of a number of HAs, inhibition of
fusion could contribute to infectivity neutralization. How-
ever, the direct correlation between neutralization of in-
fectivity and inhibition of binding to cells by the antibod-
ies studied here (Fig. 3) suggests that they neutralize
infectivity by preventing receptor binding and that inhibi-
tion of membrane fusion does not contribute significantly
to neutralization.
Concluding remarks
Our results highlight two features of the antibody in-
hibition of virus binding to cells which affect neutraliza-
tion of infectivity:
First, the average number of virus-bound antibodies
required for neutralization is between 60 and 110 with an
estimated number of HA trimers per virion of about 300
(Cusack et al., 1985) (larger estimates have also been
proposed by Taylor et al., 1987). This is not inconsistent
with the single-hit kinetics of viral neutralization that
have been observed (Schofield et al., 1997), as noted and
reviewed elsewhere (Dimmock, 1995; Klasse and Moore,
1996; Parren and Burton, 2001).
Second, the antibody concentration required to
achieve neutralization, between 2  1010 M for
HC19(157) and 108 M for HC45(63), is significantly
higher than the avidities of the antibodies for viral HA
(HC19(157): KD  6  10
12 M; HC45(63): KD  100 
1012 M) (Fleury et al., 1999). These were measured at
low virus occupancy; as more antibody molecules are
bound to virus and crowding on the viral surface in-
creases, their avidity for virus HA is expected to de-
crease. This would explain the observed difference be-
tween antibody avidity for viral HA and the antibody
concentration required for neutralization of viral infectiv-
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ity. The concentration of an antibody at which neutraliza-
tion occurs is, therefore, a combined function of the
antibody’s affinity for HA and of the occupancy of anti-
bodies on the virus particle at which neutralization oc-
curs, which depends on the epitope recognized.
MATERIALS AND METHODS
Virus and antibodies
X31 virus and antibodies were purified as described
(Bizebard et al., 1994; Brand and Skehel, 1972; Gigant et
al., 1995, 2000). 125I-labeling of virus and antibodies was
performed according to Bolton and Hunter (1973).
Neutralization of infectivity
For 1 h 100 PFU of unlabeled X31 virus or 125I-labeled
X31 virus was incubated with twofold dilutions of anti-
body or of labeled antibody at room temperature. The
mixtures were added to confluent MDCK cells and
plaques were developed as described (Appleyard and
Maber, 1974). Incubation of the cells with inoculum was
done at room temperature when neutralization was com-
pared to antibody binding to virus and at 4°C when
neutralization was compared to virus binding to cells.
Antibody binding to virus
Twofold dilutions of 125I-labeled antibodies were incu-
bated for 1 h with 10 HA units (in the cases of HC19(157)
or HC63(226)) or 100 HA units (in the case of HC45(63))
of X31 virus in 1 ml PBS, 0.25% gelatin. An amount of 950
l of the mixture was layered on 2 ml 10% sucrose in 3-ml
Beckman tubes and centrifuged at 70K rpm for 10 min at
4°C in a Beckman 100.3 rotor, using a TL100 centrifuge.
We determined with 125I-labeled virus that under these
conditions all the virus is pelleted. The radioactivity of the
pellet was counted and virus-bound radioactivity was the
difference in counts measured from samples with and
without virus. The antibody:HA ratio in each sample was
deduced from the number of virus-bound antibody mol-
ecules in the sample and from the number of HA mono-
mers on the virus (3.7  1014  1.3  1014 M in 10 HA
units); this was evaluated by comparing the intensity of
the HA band of whole virus on a Coomassie-stained
SDS–PAGE gel to those of known amounts of HA.
Inhibition of virus binding to cells
Twofold dilutions of antibody were incubated for 1 h
with 10 HA units of 125I-labeled X31 virus in 1 ml PBS at
4°C. The inoculum (0.5 ml) was incubated with MDCK
cells in duplicate at 4°C for 1 h. Each well was washed
twice with cold PBS; the cells were then lysed with 1 ml
1 M NaOH for 30 min at 37°C and the radioactivity was
counted.
ACKNOWLEDGMENTS
We thank R. Gonzalves and D. Stevens for excellent assistance. This
work was supported by the C.N.R.S., the M.R.C., and by a grant from the
E.U. Biomed program (Contract BMH4–97-2393).
REFERENCES
Appleyard, G., and Maber, H. B. (1974). Plaque formation by influenza
viruses in the presence of trypsin. J. Gen. Virol. 25, 351–357.
Barbey-Martin, C., Gigant, B., Bizebard, T., Calder, L. J., Wharton, S. A.,
Skehel, J. J., and Knossow, M. (2002). An antibody that prevents the
hemagglutinin low pH fusogenic transition. Virology 294, 70–74.
Bizebard, T., Daniels, R., Kahn, R., Golinelli-Pimpaneau, B., Skehel, J. J.,
and Knossow, M. (1994). Refined three-dimensional structure of the
Fab fragment of a murine IgG1, antibody. Acta Crystallogr. D 50,
768–777.
Bizebard, T., Gigant, B., Rigolet, P., Rasmussen, B., Diat, O., Bo¨secke, P.,
Wharton, S., Skehel, J. J., and Knossow, M. (1995). Structure of
influenza virus hemagglutinin complexed with a neutralizing anti-
body. Nature 376, 92–94.
Bolton, A. E., and Hunter, W. M. (1973). The labelling of proteins to high
specific radioactivities by conjugation to a 125I-containing acylating
agent. Biochem. J. 133, 529–539.
Brand, C. M., and Skehel, J. J. (1972). Crystalline antigen from the
influenza virus envelope. Nat. New Biol. 238, 145–147.
Colonno, R. J., Callahan, P. L., Leippe, D. M., Rueckert, R. R., and
Tomassini, J. E. (1989). Inhibition of rhinovirus attachment by neutral-
izing monoclonal antibodies and their Fab fragments. J. Virol. 63(1),
36–42.
Cusack, S., Ruigrok, R. W. H., Krygsman, P. C. J., and Mellenna, J. E.
(1985). Structure and composition of influenza virus, a small-angle
neutron scattering study. J. Mol. Biol. 186, 565–582.
Daniels, R. S., Douglas, A. R., Skehel, J. J., and Wiley, D. C. (1983).
Analyses of the antigenicity of influenza hemagglutinin at the pH
optimum for virus-mediated membrane fusion. J. Gen. Virol. 64, 1657–
1662.
Daniels, R. S., Jeffries, S., Yates, P., Schild, G. C., Rogers, G. N., Paulson,
J. C., Wharton, S. A., Douglas, A. R., Skehel, J. J., and Wiley, D. C.
(1987). The receptor-binding and membrane-fusion properties of in-
fluenza virus variants selected using anti-hemagglutinin monoclonal
antibodies. EMBO J. 6(5), 1459–1465.
Dimmock, N. J. (1995). Update on the neutralization of animal viruses.
Rev. Med. Virol. 5, 165–179.
Flamand, A., Raux, H., Gaudin, Y., and Ruigrok, R. W. (1993). Mecha-
nisms of rabies virus neutralization. Virology 194, 302–313.
Fleury, D., Barre`re, B., Bizebard, T., Daniels, R. S., Skehel, J. J., and
Knossow, M. (1999). A complex of influenza hemagglutinin with a
neutralizing antibody that binds outside the virus receptor binding
site. Nat. Struct. Biol. 6(6), 530–534.
Gerhard, W., Mozdzanowska, K., Furchner, M., Washko, G., and Maiese,
K. (1997). Role of the B-cell response in recovery of mice from
primary influenza virus infection. Immunol. Rev. 159, 95–103.
Gigant, B., Barbey-Martin, C., Bizebard, T., Fleury, D., Daniels, R. S.,
Skehel, J. J., and Knossow, M. (2000). A neutralizing antibody Fab-
influenza hemagglutinin complex with an unprecedented 2:1 stoichi-
ometry: Characterization and crystallization. Acta Crystallogr. D 56,
1067–1069.
Gigant, B., Fleury, D., Bizebard, T., Skehel, J. J., and Knossow, M. (1995).
Crystallization and preliminary X-ray diffraction studies of complexes
between an influenza hemagglutinin and Fab fragments of two dif-
ferent monoclonal antibodies. Proteins Struct. Funct. Genet. 23, 115–
117.
He, R. T., Innis, B. L., Nisalak, A., Usawattanakul, W., Wang, S., Kalay-
anarooj, S., and Anderson, R. (1995). Antibodies that block virus
attachment to Vero cells are a major component of the human
neutralizing antibody response against dengue virus type 2. J. Med.
Virol. 45(4), 451–461.
297NEUTRALIZATION OF INFLUENZA VIRUS INFECTIVITY
Klasse, P. J., and Moore, J. P. (1996). Quantitative model of antibody- and
soluble CD4-mediated neutralization of primary isolates and T-cell
line-adapted strains of human immunodeficiency virus type 1. J. Virol.
70,(6), 3668–3677.
Klasse, P. J., and Sattentau, Q. J. (2001). Mechanisms of virus neutral-
ization by antibody. Curr. Top. Microbiol. Immunol. 260, 87–108.
Palladino, G., Mozdzanowska, K., Washko, G., and Gerhard, W. (1995).
Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of
IgM or IgA isotypes can cure influenza virus pneumonia in SCID
mice. J. Virol. 69(4), 2075–2081.
Parren, P. W., and Burton, D. R. (2001). The antiviral activity of antibodies
in vitro and in vivo. Adv. Immunol. 77, 195–262.
Sauter, N. K., Bednarski, M. D., Wurzburg, B. A., Hanson, J. E., White-
sides, G. M., Skehel, J. J., and Wiley, D. C. (1989). Hemagglutinins
from two influenza virus variants bind to sialic acid derivatives with
millimolar dissociation constants: A 500-MHz proton nuclear mag-
netic resonance study. Biochemistry 28, 8388–8396.
Schofield, D. J., Stephenson, J. R., and Dimmock, N. J. (1997). High and
low efficiency neutralization epitopes on the hemagglutinin of type A
influenza virus. J. Gen. Virol. 78, 2441–2446.
Skehel, J. J., Stevens, D. J., Daniels, R. S., Douglas, A. R., Knossow, M.,
Wilson, I. A., and Wiley, D. C. (1984). A carbohydrate side chain on
hemagglutinin of Hong Kong influenza viruses inhibits recognition by
a monoclonal antibody. Proc. Natl. Acad. Sci. USA 81, 1779–1783.
Skehel, J. J., and Wiley, D. C. (2000). Receptor binding and membrane
fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Bio-
chem. 69, 531–69.
Smith, T. J., Olsen, N. H., Cheng, R. H., Liu, H., Chase, E., Le, W. M.,
Leippe, D. M., Mosser, A. G., Rueckert, R. R., and Baker, T. S. (1993).
Structure of human rhinovirus complexed with fab fragments from a
neutralizing antibody. J. Virol. 67, 1148–1158.
Taylor, H. P., Armstrong, S. J., and Dimmock, N. J. (1987). Quantitative
relationships between an influenza virus and neutralizing antibody.
Virology 159, 288–298.
Ugolini, S., Mondor, I., Parren, P. W., Burton, D. R., Tilley, S. A., Klasse,
P. J., and Sattentau, Q. J. (1997). Inhibition of virus attachment to
CD4 target cells is a major mechanism of T cell line-adapted HIV-1
neutralization. J. Exp. Med. 186(8), 1287–1298.
Wiley, D. C., and Skehel, J. J. (1987). The structure and function of the
hemagglutinin membrane glycoprotein of influenza virus. Ann. Rev.
Biochem. 56, 365–394.
298 KNOSSOW ET AL.
